Related Experiment Videos
Gene therapy for liver metastases
Roman Havlik1, Long R Jiao, Joanna Nicholls
1Liver Surgery Section, Department of Surgical Oncology and Technology, Faculty of Medicine, Imperial College, Hammersmith Hospital Campus, London, UK.
Abstract:
Although resection is currently the only curative approach for metastatic liver cancer, only a small number of cases are suitable for this procedure. In the past few years, gene therapy has emerged as an appealing treatment option for liver cancer. Phase I and II clinical trials have been conducted in patients with either primary or secondary liver cancer using a variety of genes including tumor-suppressor gene p53, suicide genes, immune genes, and replication-competent oncolytic adenoviruses. The results have shown that, although gene therapy has been well tolerated and toxicity has been low, the clinical benefit has so far been marginal. Gene therapy as a definitive treatment for liver metastases remains limited, at least for the time being, but it may be useful as an adjuvant treatment in combination with radiotherapy, chemotherapy, and/or surgery to achieve disease-free survival.
Insights
Gene therapy shows promise for liver cancer treatment, with low toxicity observed in clinical trials. However, its current clinical benefit is marginal, suggesting its best use may be alongside traditional therapies for improved outcomes.
Area of Science:
- Oncology
- Gene Therapy
- Hepatology
Background:
- Resection is the only curative option for metastatic liver cancer, but it is only suitable for a small patient subset.
- Gene therapy is emerging as a potential alternative treatment for primary and secondary liver cancer.
- Previous studies have explored various gene types, including tumor-suppressor gene p53, suicide genes, immune genes, and oncolytic adenoviruses.
Purpose of the Study:
- To evaluate the safety and efficacy of gene therapy in patients with liver cancer.
- To assess the clinical benefit of gene therapy as a standalone or adjuvant treatment for liver metastases.
Main Methods:
- Conducted Phase I and II clinical trials involving patients with primary or secondary liver cancer.
- Administered various gene therapies, including tumor-suppressor gene p53, suicide genes, immune genes, and replication-competent oncolytic adenoviruses.
Main Results:
- Gene therapy was generally well-tolerated with low toxicity in clinical trials.
- The observed clinical benefit of gene therapy for liver cancer has been marginal to date.
- Gene therapy alone is currently limited as a definitive treatment for liver metastases.
Conclusions:
- Gene therapy is a safe and tolerable treatment for liver cancer.
- Further research is needed to enhance the efficacy of gene therapy for liver metastases.
- Gene therapy may serve as an effective adjuvant treatment when combined with conventional therapies like surgery, chemotherapy, or radiotherapy to improve disease-free survival.